Pharma stock, which manufactures and markets pharmaceuticals and chemicals, surged nearly 9 percent following a 25.56 percent year-on-year growth in net profit for Q2 FY25.
Share price variations:
With a market capitalization of Rs. 9,395.25 crores, Procter & Gamble Health Ltd. rose to an intraday high of Rs. 5,742.40 representing an 8.6 percent increase from its previous closing price of Rs. 5,287.00 per share.
Reason for the Rise:
According to exchange filings, Procter & Gamble Health Ltd. reported a 25.5 percent year-on-year increase in net profit for Q2 FY25, reaching Rs 82.33 crore, up from Rs 65.57 crore in Q2 FY24. On a quarter-on-quarter basis, net profit surged by 390.6 percent, rising from Rs. 16.78 crore in Q1 FY25.
Their total revenue grew by 1.8 percent year-on-year to Rs. 316.69 crore, compared to Rs. 310.98 crore in the same period last year. Sequentially, revenue increased by 10.72 percent from Rs. 286.01 crore in Q1 FY25.
For the first half of FY25, revenue decreased by 2.4 percent to Rs. 602.7 crores, down from Rs.617.62 crores in H1 FY24, while net profit showed an increase of 3.8 percent, reaching Rs. 99.11 crores compared to Rs. 95.39 crores in the previous year.
About the company:
P&G Health Ltd is engaged in the business of manufacturing and marketing pharmaceuticals and chemicals. The company is one the India’s largest VMS companies, manufacturing and marketing vitamins, minerals, and supplements.
The company owns and operates 1 manufacturing facility in Goa with a capacity of 260 Mio ampoules p.a. and with a capacity of over 744 Mio capsules p.a. The site also exports to 13 countries within P&G Personal Healthcare International.
Written By: Joseph Pv
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
